NCT02560766: An overdue trial by XenoPort, Inc.
This trial is overdue. It was due to report 8 months, 3 weeks ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT02560766 |
|---|---|
| Title | A Multicenter, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary RLS |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 29, 2016 |
| Completion date | Oct. 31, 2023 |
| Required reporting date | Oct. 31, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | July 18, 2025 |
| Days late | 260 |